Logo

Abbott Selects Two Antigen Targets from Celera Genomics for Cancer Therapeutic Development

Apr 15, 2005

NEW YORK, April 15 (GenomeWeb News) - Celera Genomics announced yesterday that two of its antigen targets have been selected for further investigation by Abbott for cancer therapeutic development.

 

The targets were developed by Celera Genomics over the last year, since the company signed a collaboration agreement with Abbott to use proteomic technologies to develop cell surface antigens that could serve as cancer therapeutics.

 

Kathy Ordonez, president of Celera Genomics, said the agreement is "an important milestone" toward the company's goal of developing a pipeline of therapies derived from its proteomics platform.

 

Financial terms for the agreement were not provided.

Breaking News
The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.